Comparison of Changes in Anxiety and Depression Level Between Dabigatran and Warfarin Use in Patients With Atrial Fibrillation

Basit Öğe Kaydı
dc.contributor.authorTürker, Yasin
dc.contributor.authorEkinözü, İsmail
dc.contributor.authorAytekin, Seda
dc.contributor.authorTürker, Yasemin
dc.contributor.authorBaşar, Cengiz
dc.contributor.authorBaltacı, Davut
dc.contributor.authorKaya, Ertuğrul
dc.date.accessioned2020-04-30T22:41:14Z
dc.date.available2020-04-30T22:41:14Z
dc.date.issued2017
dc.departmentDÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.descriptionKaya, Ertugrul/0000-0003-0081-682Xen_US
dc.descriptionWOS: 000394912700008en_US
dc.descriptionPubMed: 26276685en_US
dc.description.abstractWe hypothesized that patients taking warfarin require frequent hospital follow-up and they are at higher risk for complications, so the incidence of depression and anxiety is higher in patients with atrial fibrillation (AF) in the period of taking warfarin compared to the period of taking dabigatran. Fifty patients having AF without valvular diseases under treatment of warfarin in whom a transition to dabigatran was planned were consecutively enrolled in this study and followed up prospectively between July 2013 and July 2014. All patients completed Beck Depression Inventory and Hamilton Anxiety Scale (HAS) at the initiation of study and 6 months after initiation of study. Of the patients enrolled in the study, age, gender, smoking status, and comorbidities were questioned. A total of 50 patients (28 women; mean age 74.6 +/- 8.7 years) treated with warfarin in whom a transition to dabigatran was planned were included. Basal mean value of BDS (15.6 +/- 7.8 vs 11.5 +/- 4.8, P < .001) and HAS (16.8 +/- 10.4 vs 12.6 +/- 8.1, P < 0.001) was significantly higher in patients when they used warfarin than when they switched to dabigatran. In categorical analysis, frequency of patients with depression (mild, moderate, and severe) was significantly higher in period of warfarin use than after dabigatran transition (n = 24, 48% vs n = 14, 28%, P = .039). Our study demonstrates that patients with nonvalvular AF under treatment of dabigatran had lower BDS and HAS scores compared to warfarin. These findings suggest that dabigatran may increase quality of life and decrease morbidity and mortality due to reduction in anxiety and depression.en_US
dc.identifier.doi10.1177/1076029615600792en_US
dc.identifier.endpage167en_US
dc.identifier.issn1076-0296
dc.identifier.issn1938-2723
dc.identifier.issue2en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage164en_US
dc.identifier.urihttps://doi.org/10.1177/1076029615600792
dc.identifier.urihttps://hdl.handle.net/20.500.12684/3149
dc.identifier.volume23en_US
dc.identifier.wosWOS:000394912700008en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherSage Publications Incen_US
dc.relation.ispartofClinical And Applied Thrombosis-Hemostasisen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectanxietyen_US
dc.subjectdepressionen_US
dc.subjectwarfarinen_US
dc.subjectdabigatranen_US
dc.titleComparison of Changes in Anxiety and Depression Level Between Dabigatran and Warfarin Use in Patients With Atrial Fibrillationen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
3149.pdf
Boyut:
104.85 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu